Efficient replication of adenovirus despite the overexpression of active and nondegradable p53

Cancer Research

Volumn 61, Issue 15, 2001, Pages 5941-5947

  Koch, Philipp ^a   Gatfield, Jennifer ^a   Löber, Christian ^a   Hobom, Urs ^a   Lenz Stöppler, Claudia ^a   Dobbelstein, Matthias ^a   Roth, Judith ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53; RECOMBINANT PROTEIN; VIRUS PROTEIN;

ADENOVIRUS; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CELL DIVISION; CONTROLLED STUDY; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; DNA-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GENES, TUMOR SUPPRESSOR; HUMANS; NUCLEAR PROTEINS; PROTEIN BIOSYNTHESIS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; VIRUS REPLICATION;

EID: 0035422207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells
2. Adenovirus E1b oncoprotein tethers a transcriptional repression domain to p53
3. Inhibition of p53 transactivation required for transformation by adenovirus early IB protein
4. Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein
5. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins
6. Role of adenovirus types 5 and 12 early region 1b tumor antigens in oncogenic transformation
7. Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor
8. Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex
9. Oncogenic potential of the adenovirus E4orf6 protein
10. Regulation of p53 levels by the E1B 55-kilodalton protein and E4orf6 in adenovirus-infected cells
11. The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells
12. Inactivation of p53 but not p73 by adenovirus type 5 E1B 55-kilodalton and E4 34-kilodalton oncoproteins
13. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53
14. Monoallelically expressed gene related to p53 at Ip36, a region frequently deleted in neuroblastoma and other human cancers
15. p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: A third member of the p53 family?
16. Non-p53 p53RE binding protein, a human transcription factor functionally analogous to P53
17. Cloning and functional analysis of human p51, which structurally and functionally resembles p53
18. A second p53-related protein, p73L, with high homology to p73
19. Two new p73 splice variants, γ and δ, with different transcriptional activity
20. A new human p53 homologue
21. A novel protein with strong homology to the tumor suppressor p53
22. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities
23. Distinct regulation of p53 and p73 activity by adenovirus E1A, E1B, and e4orf6 proteins
24. Viral oncoproteins discriminate between p53 and the p53 homolog p73
25. Adenovirus e4orf6 oncoprotein modulates the function of the p53-related protein, p73
26. Adenoviridae. The viruses and their replication
27. Replicating viruses as selective cancer therapeutics
28. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells
29. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection
30. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status
31. Efficacy with replication-selective adenovirus plus cisplatin-based chemotherapy: Dependence on sequencing but not p53 functional status or route of administration
32. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: Intratumoral spread and distribution effects
33. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy
34. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
35. ONYX-015: Clinical data are encouraging
36. A Phase I study of Onyx-015, an E1B-attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer
37. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy
38. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients
39. A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
40. A prospective Phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience)
41. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an K1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A Phase II trial
42. p53-dependent cell death/apoptosis is required for a productive adenovirus infection
43. Replication of ONYX-015. A potential anticancer adenovirus, is independent of p53 status in tumor cells
44. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection
45. The replicative capacities of large E1B-null group A and group C adenoviruses are independent of host cell p53 status
46. Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and 32 δE1B adenovirus replication in human cells
47. p53-independent and -dependent requirements for E1B-55K in adenovirus type 5 replication
48. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: The importance of the adenoviral E1b-55kD gene
49. ARF, participates in a regulatory feedback loop with p53 and MDM2
50. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways
51. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
52. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant d11520 (ONYX-015)
53. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport
54. The adenovirus E1B-55K transforming polypeptide modulates transport or cytoplasmic stabilization of viral and host cell mRNAs
55. Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence
56. E1B 55-kilodalton-associated protein: A cellular protein with RNA-binding activity implicated in nucleocytoplasmic transport of adenovirus and cellular mRNAs
57. RNA-binding activity of the E1B 55-kilodalton protein from human adenovirus type 5
58. The adenovirus E1B 55 kd protein influences mRNA transport via an intranuclear effect on RNA metabolism
59. The nuclear export signal within the e4orf6 protein of adenovirus type 5 supports virus replication and cytoplasmic accumulation of viral mRNA
60. Dissection of functional domains in the adenovirus 2 early 1B 55K polypeptide by suppressor-linker insertional mutagenesis
61. A simplified system for generating recombinant adenoviruses
62. Intracistronic complementation reveals a new function of SV40 T antigen that cooperates with Rb and p53 binding to stimulate DNA synthesis in quiescent cells
63. WAF1, a potential mediator of p53 tumor suppression
64. Adenovirus type 5 E4orf3 protein relieves p53 inhibition by E1B-55- kilodalton protein
65. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses
66. Large E1B proteins of adenovirus types 5 and 12 have different effects on p53 and distinct roles in cell transformation
67. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53
68. E1A signaling to p53 involves the p19(ARF) tumor suppressor
69. Subtractive hybridization of mRNA from early passage and senescent endothelial cells
70. Wild-type p53 is not a negative regulator of simian virus 40 DNA replication in infected monkey cells
71. An ovine adenovirus vector lacks transforming ability in cells that are transformed by AD5 E1A/B sequences
72. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein
73. Adenovirus E1B 19-kDa death suppressor protein interacts with Bax but not with Bad
74. Surfing the p53 network
75. Identification and classification of p53-regulated genes
76. Analysis of p53-regulated gene expression patterns using oligonucleotide arrays
77. Replicative adenoviruses for cancer therapy
78. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
79. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
80. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein
81. Induction of apoptosis by adenovirus E4orf4 protein is specific to transformed cells and requires an interaction with protein phosphatase 2A
82. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas
83. Studies on the use of viruses in the treatment of carcinoma of the cervix